[Federal Register Volume 61, Number 171 (Tuesday, September 3, 1996)]
[Notices]
[Pages 46478-46479]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-22393]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute: Opportunity for a Cooperative Research
and Development Agreement (CRADA) for the Scientific and Commercial
Development of Fusion Proteins That Include Antibody and Non-Antibody
Portions
AGENCY: National Cancer Institute, National Institutes of Health, PHS,
DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (DHHS) seeks one
or more companies that can collaboratively pursue the pre-clinical and
clinical development of Fusion Proteins That Include Antibody and Non-
Antibody Portions. The following disease states are of interest:
neoplasia, arteriosclerosis, tumor vascularization, fibrotic diseases,
psoriasis and wound healing. The National Cancer Institute, Laboratory
of Cellular and Molecular Biology has developed an assay system to
identify receptor agonists and antagonists using fusion protein
technology. The selected sponsor will be awarded a CRADA with the
National Cancer Institute for the co-development of agents identified
using the fusion protein technology.
ADDRESS: Questions about this opportunity may be addressed to Jeremy A.
Cubert, M.S., J.D., Office of Technology Development, NCI, 6120
Executive Blvd. MSC 7182, Bethesda, MD 20892-7182, Phone: (301) 496-
0477, Facsimile: (301) 402-2117, from whom further information may be
obtained.
DATE: In view of the important priority of developing new agents for
the treatment or prevention of cancer, interested parties should notify
this office in writing no later than October 18, 1996. Respondents will
then be provided an additional 30 days for the filing of formal
proposals.
SUPPLEMENTARY INFORMATION: ``Cooperative Research and Development
Agreement'' or ``CRADA'' means the anticipated joint agreement to be
entered into by NCI pursuant to the Federal Technology Transfer Act of
[[Page 46479]]
1986 and amendments (including 104 P.L. 133) and Executive Order 12591
of October 10, 1987 to collaborate on the specific research project
described below.
The Government is seeking one or more companies which, in
accordance with the requirements of the regulations governing the
transfer of agents in which the Government has taken an active role in
developing (37 CFR 404.8), can further develop the identified compounds
and related diagnostic methods through Federal Food and Drug
Administration approval and to a commercially available status to meet
the needs of the public and with the best terms for the Government. The
government has applied for domestic and foreign patent applications
directed to Fusion Proteins That Include Antibody and Non-Antibody
Portions.
The Fusion Proteins comprise an IgG sequence covalently joined at
the IgG hinge and Fc domain to a non-antibody effector domain such as a
ligand, toxin, or receptor. The effector domain or IgG non-antibody
portion may be linked to a heterologous signal peptide to facilitate
secretion. The resulting fusion protein exhibits the effector
properties of both the antibody and non-antibody portions. Applications
of this technology include development of diagnostic methods to monitor
binding and expression of a protein of interest in vitro, in vivo and
in situ (i.e. immunohistochemistry). In addition, the technology can be
used to identify agonists and antagonists that modulate the binding of
an effector molecule to its target. Fusion proteins may also be
employed as a therapeutic to deliver radiation, a cytotoxic agent or a
drug directly to a target cell.
The LCMB, Division of Basic Sciences, NCI is interested in
establishing a CRADA with one or more companies to assist in the
development of diagnostic, screening and therapeutic applications of
the technology. The Government will provide all available expertise and
information to date and will jointly pursue pre-clinical and clinical
studies as required, giving the company full access to existing data
and data developed pursuant to the CRADA. The successful company will
provide the necessary scientific, financial and organizational support
to establish clinical efficacy and possible commercial status of
subject compounds and/or diagnostic and therapeutic applications.
The expected duration of the CRADA will be two (2) to five (5)
years.
The role of the National Cancer Institute, includes the following:
1. Construction of fusion proteins comprising a molecule of
interest covalently joined to an IgG hinge and FC antibody regions.
2. Expression and harvesting of the resulting fusion protein from
conditioned medium of a suitable transfectant such as NIH 3T3 cells.
3. Develop a screen of ligand-HFc on receptor or receptor-HFc on
ligand to identify putative agonists and antagonists.
4. Conduct in vitro studies to identify putative agonists and/or
antagonists by screening libraries of compounds.
5. Conduct in vitro and in vivo studies to characterize the
properties of putative agonists and/or antagonists.
6. Evaluation of test results.
7. Preparation of manuscripts for publication.
Relevant Government intellectual property rights are available for
licensing through the Office of Technology Transfer, National
Institutes of Health.
FOR FURTHER INFORMATION CONTACT Susan Rucker, J.D., NIH Office of
Technology Transfer, 6011 Executive Blvd, Suite 325, Rockville, MD
20852, Phone: (301) 496-7056 (ext. 245); Facsimile: (301) 402-0220.
The role of the collaborator company, includes the following
For agonist/antagonist screening:
1. Provide growth factor or receptor cDNA clones for fusion protein
construction if not available in NCI/LCMB clone bank
2. Scale-up production of fusion proteins constructed by NCI if
required
3. Conduct in vitro studies to identify putative antagonists/agonists
by screening libraries of compounds
4. Conduct in vitro and in vivo studies to characterize the properties
of putative antagonists/agonists
5. Conduct clinical studies of best candidates
For ligand-mediated histochemical experiments:
1. Test conditioned medium for suitability in histochemical experiments
2. Screen tumor samples or biopsies for reactivity
3. Conduct clinical studies of diagnostic test
Criteria for choosing the company include its demonstrated
experience and commitment to the following:
1. Scientific expertise in and demonstrated commitment to the
treatment of neoplasia, arteriosclerosis, fibrotic diseases and related
disorders.
2. Scientific expertise in and demonstrated commitment to the
development of drug delivery systems.
3. Experience in preclinical and clinical drug development.
4. Experience and ability to produce, package, market and
distribute pharmaceutical products.
5. Experience in the monitoring, evaluation and interpretation of
the data from investigational agent clinical studies under an IND.
6. A willingness to cooperate with the NCI in the collection,
evaluation, publication and maintaining of data from pre-clinical
studies and clinical trials regarding the subject compounds.
7. Provide defined financial and personnel support for the CRADA to
be mutually agreed upon.
8. An agreement to be bound by the DHHS rules involving human and
animal subjects.
9. The aggressiveness of the development plan, including the
appropriateness of milestones and deadlines for preclinical and
clinical development.
10. Provisions for equitable distribution of patent rights to any
CRADA inventions. Generally the rights of ownership are retained by the
organization which is the employer of the inventor, with (1) an
irrevocable, nonexclusive, royalty-free license to the Government and
(2) an option for the collaborator to elect an exclusive or
nonexclusive license to Government owned rights under terms that comply
with the appropriate licensing statutes and regulations.
Dated: August 14, 1996.
Thomas D. Mays,
Director, Office of Technology Development, OD, NCI.
[FR Doc. 96-22393 Filed 8-30-96; 8:45 am]
BILLING CODE 4140-010-M